Citius Pharmaceuticals, Inc. (CTXR) Return on equity 2017–2022
Citius Pharmaceuticals, Inc. (CTXR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-32.7%FY2022 · since FY2017: -47.3% → -32.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -32.7% | -15.3 pp |
| FY2021 | -17.4% | +34.7 pp |
| FY2020 | -52.1% | +5.2 pp |
| FY2019 | -57.3% | -16.4 pp |
| FY2018 | -40.9% | +6.4 pp |
| FY2017 | -47.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice